Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.

Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A.

Oncotarget. 2018 Jul 13;9(54):30268-30278. doi: 10.18632/oncotarget.25666. eCollection 2018 Jul 13.


Intravascular Volume Profiles in Patients With Class I and II Systolic Heart Failure: Heterogeneity and Volume Overload Are Common Even in Mild Heart Failure.

Miller WL, Albers DP, Gansen DN, Mullan BP.

J Card Fail. 2018 Jul;24(7):417-424. doi: 10.1016/j.cardfail.2017.09.010. Epub 2017 Oct 2.


Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR.

Cardiovasc Intervent Radiol. 2013 Jun;36(3):714-23. doi: 10.1007/s00270-012-0481-2. Epub 2012 Oct 24.


Liver transplantation after radioembolization in a patient with unresectable HCC.

Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL.

Nat Rev Gastroenterol Hepatol. 2009 Nov;6(11):679-83. doi: 10.1038/nrgastro.2009.165. Review.


Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.

Fleming CJ, Andrews JC, Wiseman GA, Gansen DN, Roberts LR.

J Vasc Interv Radiol. 2009 Nov;20(11):1460-3. doi: 10.1016/j.jvir.2009.07.033.


A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.


A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.

Clin Cancer Res. 2003 May;9(5):1639-47.

Supplemental Content

Loading ...
Support Center